HanchorBio Advances Toward TWSE Innovation Board Listing to Accelerate Global Clinical Development, Platform Expansion, and International Partnering
Listing milestone positions HanchorBio to strengthen institutional visibility, advance its FBDB™ platform, and expand a growing pipeline spanning oncology and broader immune-mediated diseases
[Taipei, Shanghai, San Francisco | March 24, 2026] – HanchorBio, Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation multifunctional biologics across oncology and immune-related diseases, today announced that it has received approval from the Board of Directors of the Taiwan Stock Exchange to list on the TWSE Innovation Board, with listing anticipated in the second quarter of 2026, subject to completion of the remaining customary procedures.
For HanchorBio, the transition to the TWSE Innovation Board is more than a financing event. It represents a strategic milestone intended to strengthen the Company’s capital markets foundation for its next phase of growth, including advancing global clinical development, expanding its pipeline through the proprietary Fc-Based Designer Biologics (FBDB™) platform, increasing visibility with institutional investors and multinational partners, and further reinforcing the operational and governance infrastructure required to support the transition towards a globally recognized biotechnology company.
Founded in 2020, HanchorBio is building a differentiated immunology company grounded in fundamental immune biology and innovative molecular engineering. Its FBDB™ platform is designed to generate multifunctional biologics that precisely modulate key immune pathways, with the goal of overcoming limitations associated with conventional single-target approaches.
Rather than operating as a single-asset company, HanchorBio is leveraging FBDB™ to build a broader portfolio of product candidates based on AI-guided engineering strategies and immunological mechanism-of-action synergies. The Company believes this platform-based model offers strategic flexibility and long-term value creation by enabling multiple opportunities across distinct disease areas that have high unmet medical needs.
“HanchorBio was built to do more than just advance individual programs,” said Scott Liu, PhD, Founder, Chairman, and CEO of HanchorBio. “We are building a company with scientific discipline, clinical ambition, and a scalable platform capable of generating differentiated, highly innovative biologics with global impact. Advancing toward the TWSE Innovation Board is an important milestone in strengthening our ability to execute that strategy.”
HanchorBio’s lead oncology programs, HCB101 and HCB301, illustrate the translational breadth of its platform and its commitment to developing next-generation breakthrough immunotherapies.
HCB101, the company’s lead innate immune checkpoint program, is currently in clinical development for solid tumors and has advanced into Phase 1b/2 studies. The program is designed to target the CD47-SIRPα axis while maintaining a differentiated hematologic profile. In June 2025, HanchorBio entered into its first regional licensing agreement for HCB101, with a total potential deal value of up to US$202 million, providing meaningful external validation of both the asset and the Company’s partnering strategy. HanchorBio continues to advance HCB101 globally while pursuing additional strategic collaboration opportunities.
HCB301 is a tri-specific fusion protein developed using the FBDB™ platform and engineered to coordinate SIRPα, PD-L1, and TGF-β modulations within a single molecule. Currently in Phase 1 clinical development, this program reflects HanchorBio’s broader capability of designing multifunctional biologics capable of modulating multiple immune-suppressive pathways within the tumor microenvironment.
Beyond its lead oncology programs HCB101 and HCB301, HanchorBio is also expanding its platform into broader autoimmune diseases, including HCB206 and HCB307, reflecting the Company’s longer-term strategy to apply its immune-engineering capabilities across multiple disease areas.
Looking ahead, HanchorBio intends to continue advancing HCB101 and HCB301 in the clinic while expanding its pipeline across oncology and autoimmune diseases. The Company also plans to extend the reach of its platform through internal development and selective strategic collaborations. HanchorBio expects the TWSE Innovation Board listing to support broader institutional engagement, provide greater capital flexibility, and increase visibility as it continues its pursuit of long-term global growth.
About HanchorBio (7827.TPEx)
HanchorBio is a pioneering global, clinical-stage immunology company headquartered in Taipei, Shanghai, and the San Francisco Bay Area. It is at the forefront of developing next-generation, multifunctional biologics for oncology and immune-mediated diseases. Its proprietary Fc-Based Designer Biologics (FBDB™) platform offers unprecedented capabilities for designing differentiated therapeutic candidates that precisely modulate innate and adaptive immune pathways. HanchorBio’s expanding pipeline, including candidates such as HCB101 and HCB301, and its innovative platform-derived programs, such as HCB206 and HCB307, exemplify its commitment to addressing critical unmet medical needs through groundbreaking science, clinical excellence, and a scalable, forward-looking development strategy. For more information, please visit: www.HanchorBio.com
Forward-Looking Statements
This press release contains forward-looking statements, including those about the expected timing of the listing, future development plans, clinical progress, regulatory submissions, business strategy, capital markets activities, and partnering opportunities. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ significantly from what is described. HanchorBio has no obligation to update these statements except as required by law.
漢康-KY獲證交所董事會通過股票創新板上市
核心技術FBDB™平台開發價值高
專注創新藥物開發的漢康-KY（股票代碼：7827）今（24）日獲臺灣證券交易所董事會通過創新板上市案，主辦承銷商為國泰綜合證券，依時程預計第二季掛牌上市。
漢康-KY於2020年創立，目前實收資本額為13.02億元，為一家致力開發突破性免疫療法的生技新藥公司，鎖定癌症與自體免疫疾病二大領域。創辦人暨董事長暨執行長劉世高不僅擁有豐富的跨國製藥企業經驗，負責並參與多個藥物開發與上市過程，更有成功創業經驗，推動首個在中國大陸獲准上市的生物相似藥，以及領導團隊開發出全球首個在小細胞肺癌獲批的抗PD-1單抗藥物。漢康-KY主要股東有劉世高、安富大健康二號有限合夥以及多家投資機構與大型製藥公司等，合計前五大股東持股超過五成。
漢康-KY的核心技術FBDB™平台採模組化設計，可突破傳統生物藥在結構與功能上的限制，支援多靶點與多功能生物藥開發。此平台不僅支持單一產品研發，更具備持續產生多項研發資產的能力，為公司發展長期產品線奠定紮實基礎。
公司目前主要有2項腫瘤免疫療法推進人體臨床試驗；融合蛋白創新藥HCB101推進至臨床1b/2期試驗，在多種癌症中觀察到抗腫瘤活性，其中以二線胃癌與頭頸癌等適應症表現尤為突出，展現具潛力的廣譜抗腫瘤特性，意味著能對多種癌種產生腫瘤抑制的能力，並獲美國FDA授予治療胃癌的孤兒藥資格認定。
此外，新型三功能融合蛋白藥物HCB301則已於美國及中國大陸開展一期臨床試驗，並獲台灣TFDA核准執行一期臨床試驗，此類高度複雜的新型生物藥在全球研發項目中僅占1.6%，顯示其平台技術已具備挑戰更高複雜度藥物開發的實力。
值得注意的是，漢康-KY是少數能在早期臨床階段就成功完成全球區域授權的新藥公司。HCB101去年以2.02億美元將在中國大陸與其他特定國家等地區的市場開發與銷售權利獨家授予上海復宏漢霖，未來在HCB101獲准上市後，漢康-KY仍可享有一定比例的銷售分潤。顯見其在技術創新及未滿足的醫療需求上皆具有獨特價值。今年下半年持續推動國際授權洽談，並持續加速推進全球臨床與商業化。
此外，根據摩根大通（JPMorgan）對醫療保健投資趨勢的觀察，成熟投資者的投資重心正由單一資產公司轉向平台型公司。漢康-KY的FBDB™平台具備「multiple shots on goal」（多次射門機會或多次目標機會）價值，可同時推進HCB101、HCB301等多項新藥開發，為公司長期成長提供動能。
此次推動創新板上市，主要在於強化公司資本市場布局與國際競爭力。透過上市募資與提升股權流動性，有助於支持研發、擴充產能及吸引更多國內外機構法人投資，並進一步提升企業治理與市場能見度。同時，藉由資本市場平台加速全球市場拓展，整合更多本土及國際資源，強化整體競爭優勢。
展望今年，漢康-KY除繼續推進HCB101、HCB301的臨床試驗外，並規畫提交旗下藥物針對腫瘤與自體免疫疾病的創新藥IND申請，同時藉由與藥明生物的戰略合作，進一步推動FBDB™技術平台的拓展，加速開發多款次世代CD47/SIRPα創新融合蛋白藥物，打造永續成長引擎。公司對全年營運抱持審慎樂觀。